-
公开(公告)号：US11504419B2
公开(公告)日：2022-11-22
申请号：US16172063
申请日：2018-10-26
Applicant: BioNTech SE , TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH
Inventor： Ugur Sahin , Claudia Paret , Kirsten Vormbrock , Christian Bender , Jan Diekmann
Abstract: The present invention relates to a patient-specific tumor treatment targeting individual expression patterns of tumor antigens, in particular shared tumor antigens, and individual tumor mutations. In one aspect, the present invention relates to a method for preventing or treating cancer in a patient comprising the steps of: (i) inducing a first immune response against one or more tumor antigens in the patient, and (ii) inducing a second immune response against one or more tumor antigens in the patient wherein the second immune response is specific for cancer specific somatic mutations present in cancer cells of the patient.
-
公开(公告)号：US11459395B2
公开(公告)日：2022-10-04
申请号：US17172694
申请日：2021-02-10
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Isil Altintas , David Satijn , Rik Rademaker , Paul Parren , Ugur Sahin , Friederike Gieseke , Alexander Muik , Christian Grunwitz , Edward Van den Brink , Dennis Verzijl
IPC: C07K16/28
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
公开(公告)号：US20220257783A1
公开(公告)日：2022-08-18
申请号：US17688707
申请日：2022-03-07
Applicant: BioNTech SE
Inventor： Ozlem Tureci , Ugur Sahin , Sebastian Kreiter
Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.
-
公开(公告)号：US20220249704A1
公开(公告)日：2022-08-11
申请号：US17565842
申请日：2021-12-30
Applicant: BioNTech SE
Inventor： Ugur Sahin , Alptekin Güler , Andreas Kuhn , Alexander Muik , Annette Vogel , Kerstin Walzer , Sonja Witzel , Stephanie Hein , Özlem Türeci , Gábor Boros , Azita Josefine Mahiny , Jonas Reinholz , Katalin Karikó
IPC: A61K48/00 , A61P35/00 , A61K39/00 , A61K31/7088 , A61K39/12
Abstract: Disclosed herein are RNA polynucleotides comprising a 5′ Cap, a 5′ UTR comprising a cap proximal sequence disclosed herein, and a sequence encoding a payload. Also disclosed herein are compositions and medical preparations comprising the same, and methods of making and using the same.
-
公开(公告)号：US20220093209A1
公开(公告)日：2022-03-24
申请号：US17539157
申请日：2021-11-30
Applicant: BioNTech SE , TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gG
Inventor： Ugur Sahin , Arbel David Tadmor , John Christopher Castle , Sebastian Boegel , Martin Löwer
IPC: G16B20/20 , G16B20/00 , A61K39/00 , C12Q1/6886
Abstract: The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic or not. The methods of the invention are useful, in particular, for the provision of vaccines which are specific for a patient's tumor and thus, in the context of personalized cancer vaccines.
-
Patent Agency Ranking
公开(公告)号：US11046745B2
公开(公告)日：2021-06-29
申请号：US15741902
申请日：2015-07-14
Applicant: BioNTech SE , TRON—Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz gGmbH , JPT Peptides Technologies GmbH
Inventor： Ugur Sahin , Laura Marie Kring , Markus Fiedler , Matin Daneschdar , Hans-Ulrich Schmoldt , Ulf Reimer , Karsten Schnatbaum
IPC: A61K38/08 , C07K7/06 , G01N33/566 , G01N33/68 , C07K14/725 , A61K47/64 , A61K47/66 , C12N15/62 , A61K38/00
Abstract: The present invention provides molecules that mimic antigenic determinants of the CD3 (cluster of differentiation 3) T-cell co-receptor epsilon chain (CD3ε). These molecules compete with CD3ε for binding to a CD3ε binding domain. e.g. a CD3ε binding domain of an antibody, and are capable of detecting antibodies against CD3ε. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Additionally, they may serve as tools for anti-CD3ε antibody purification and the detection of anti-CD3ε antibodies in biological samples.
-
公开(公告)号：US10968280B2
公开(公告)日：2021-04-06
申请号：US16779011
申请日：2020-01-31
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Isil Altintas , David Satijn , Rik Rademaker , Paul Parren , Ugur Sahin , Friederike Gieseke , Alexander Muik , Christian Grunwitz
IPC: C07K16/28
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
公开(公告)号：US20200079866A1
公开(公告)日：2020-03-12
申请号：US16582534
申请日：2019-09-25
Applicant: BIONTECH SE , GENMAB A/S
Inventor： Ugur Sahin , Friederike Gieseke , Isil Altintas , David Satijn , Paul Parren
IPC: C07K16/28
Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
-
公开(公告)号：US20250011797A1
公开(公告)日：2025-01-09
申请号：US18737443
申请日：2024-06-07
Applicant: BioNTech SE , TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gG
Inventor： Florian Eberle , Ugur Sahin , Andreas Kuhn , Britta Vallazza , Mustafa Diken
Abstract: The present invention relates to nucleic acid molecules containing poly(dA:dT) regions which are stabilized in E.coli, methods of propagating such nucleic acid molecules in E.coli, methods of obtaining RNA, peptides or proteins using such nucleic acid molecules and to RNA which is obtained from such nucleic acid molecules and its use. In particular, the poly(dA:dT) regions contain at least one disruption by a sequence not encoding a sequence solely composed of A residues.
-
公开(公告)号：US20240075165A1
公开(公告)日：2024-03-07
申请号：US17988742
申请日：2022-11-16
Applicant: BioNTech SE
Inventor： Ugur Sahin , Alptekin Güler , Andreas Kuhn , Alexander Muik , Annette Vogel , Kerstin Walzer , Sonja Witzel , Stephanie Hein , Özlem Türeci
IPC: A61K48/00 , A61K9/00 , A61K9/127 , A61K9/51 , A61K31/7088 , A61K31/7105 , A61K31/711 , A61K31/7115 , A61K31/712 , A61K39/00 , A61K39/12 , A61K39/215 , A61P31/14 , A61P35/00 , B82Y5/00 , C12N7/00 , C12N15/11 , C12N15/67 , C12N15/88 , C12P19/34
CPC classification number: A61K48/0066 , A61K9/0019 , A61K9/1271 , A61K9/5123 , A61K9/5146 , A61K31/7088 , A61K31/7105 , A61K31/711 , A61K31/7115 , A61K31/712 , A61K39/0011 , A61K39/12 , A61K39/215 , A61K48/0033 , A61P31/14 , A61P35/00 , B82Y5/00 , C12N7/00 , C12N15/11 , C12N15/67 , C12N15/88 , C12P19/34 , A61K38/00 , A61K2039/53 , A61K2039/54 , A61K2039/545 , C12N2770/18022 , C12N2770/18034 , C12N2770/18071 , C12N2770/20034
Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
-
-
-
-
-
-
-
-
-
Search Results
81
records
(took 0.025 seconds)
